share_log

Chardan Capital Maintains Buy on Better Therapeutics, Lowers Price Target to $9

Benzinga ·  Mar 31, 2023 08:14

Chardan Capital analyst Keay Nakae maintains Better Therapeutics (NASDAQ:BTTX) with a Buy and lowers the price target from $14 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment